Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS · Delayed Price · Currency is USD
23.25
-0.18 (-0.77%)
At close: Jan 21, 2026
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $726.91 million as of January 22, 2026. Its market cap has decreased by -49.82% in one year.
Market Cap
726.91M
Enterprise Value
709.85M
Revenue
86.34M
Ranking
n/a
PE Ratio
229.07
Stock Price
$23.25
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 726.91M, an increase of 1,196.42%. That is a compound annual growth rate of 21.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 21, 2026 | 726.91M | 13.67% |
| Dec 30, 2025 | 639.52M | -54.14% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 782.06M |
| Glass House Brands | 723.02M |
| Elite Pharmaceuticals | 505.65M |
| Northwest Biotherapeutics | 472.88M |
| Nika Pharmaceuticals | 395.06M |
| American Oncology Network | 386.20M |
| CytoDyn | 328.21M |
| Silence Therapeutics | 238.06M |